NCT05223673 2024-08-20
COLSTAR
Servier
Phase 3 Terminated
Clinical Trials
9 trialsNCT03549338 2020-09-28
Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
Symphogen A/S
Phase 2 Terminated
NCT02540161 2020-08-05
Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
Duke University
Phase 2 Completed
NCT02083653 2019-04-16
Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer
Symphogen A/S
Phase 2 Completed
NCT03717038 2019-02-04
Sym004 Versus TAS-102 in Patients With mCRC
Symphogen A/S
Phase 3 Withdrawn
NCT01417936 2018-10-15
Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy
Symphogen A/S
Phase 2 Completed
NCT02924233 2017-08-28
Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer
Symphogen A/S
Phase 1/2 Withdrawn
NCT01955473 2017-08-23
Japanese Phase 1 Trial of Sym004 in Solid Tumors
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT02965417 2017-02-01
Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients
Symphogen A/S
Phase 2 Withdrawn